Development of new strategies for early diagnosis of mucormycosis from bench to bedside

Thomas J. Walsh, Anna Skiada, Oliver A. Cornely, Emmanuel Roilides, Ashraf Ibrahim, Theoklis Zaoutis, Andreas Groll, Olivier Lortholary, Dimitrios P. Kontoyiannis, George Petrikkos

Research output: Contribution to journalArticle

Abstract

Early diagnosis and initiation of amphotericin B (AmB) for treatment of mucormycosis increases survival from approximately 40% to 80%. The central objective of a new study of the European Confederation of Medical Mycology (ECMM) and the International Society for Human and Animal Mycology (ISHAM) Zygomycosis Working Group is to improve the clinical and laboratory diagnosis of mucormycosis. The diagnostic tools generated from this study may help to significantly improve survival from mucormycosis worldwide. The study has three major objectives: to conduct a prospective international registration of patients with mucormycosis using a well-established global network of centres; to construct a predictive risk model for patients at risk for mucormycosis; and to establish an international archive of specimens of tissues, fluids, and organisms linked from the patients enrolled into the registry that will be used for development of leading edge molecular, proteomic, metabolic and antigenic systems for mucormycosis.

Original languageEnglish (US)
Pages (from-to)2-7
Number of pages6
JournalMycoses
Volume57
Issue numbers3
DOIs
StatePublished - Dec 1 2014
Externally publishedYes

Fingerprint

Mucormycosis
Early Diagnosis
Mycology
Zygomycosis
Survival
Clinical Laboratory Techniques
Amphotericin B
Proteomics
Registries

Keywords

  • Diagnosis
  • Epidemiology
  • Mucormycosis
  • Network
  • Zygomycosis

ASJC Scopus subject areas

  • Dermatology
  • Infectious Diseases

Cite this

Walsh, T. J., Skiada, A., Cornely, O. A., Roilides, E., Ibrahim, A., Zaoutis, T., ... Petrikkos, G. (2014). Development of new strategies for early diagnosis of mucormycosis from bench to bedside. Mycoses, 57(s3), 2-7. https://doi.org/10.1111/myc.12249

Development of new strategies for early diagnosis of mucormycosis from bench to bedside. / Walsh, Thomas J.; Skiada, Anna; Cornely, Oliver A.; Roilides, Emmanuel; Ibrahim, Ashraf; Zaoutis, Theoklis; Groll, Andreas; Lortholary, Olivier; Kontoyiannis, Dimitrios P.; Petrikkos, George.

In: Mycoses, Vol. 57, No. s3, 01.12.2014, p. 2-7.

Research output: Contribution to journalArticle

Walsh, TJ, Skiada, A, Cornely, OA, Roilides, E, Ibrahim, A, Zaoutis, T, Groll, A, Lortholary, O, Kontoyiannis, DP & Petrikkos, G 2014, 'Development of new strategies for early diagnosis of mucormycosis from bench to bedside', Mycoses, vol. 57, no. s3, pp. 2-7. https://doi.org/10.1111/myc.12249
Walsh TJ, Skiada A, Cornely OA, Roilides E, Ibrahim A, Zaoutis T et al. Development of new strategies for early diagnosis of mucormycosis from bench to bedside. Mycoses. 2014 Dec 1;57(s3):2-7. https://doi.org/10.1111/myc.12249
Walsh, Thomas J. ; Skiada, Anna ; Cornely, Oliver A. ; Roilides, Emmanuel ; Ibrahim, Ashraf ; Zaoutis, Theoklis ; Groll, Andreas ; Lortholary, Olivier ; Kontoyiannis, Dimitrios P. ; Petrikkos, George. / Development of new strategies for early diagnosis of mucormycosis from bench to bedside. In: Mycoses. 2014 ; Vol. 57, No. s3. pp. 2-7.
@article{1f694c1a60ea4fc89d7a0140515b862d,
title = "Development of new strategies for early diagnosis of mucormycosis from bench to bedside",
abstract = "Early diagnosis and initiation of amphotericin B (AmB) for treatment of mucormycosis increases survival from approximately 40{\%} to 80{\%}. The central objective of a new study of the European Confederation of Medical Mycology (ECMM) and the International Society for Human and Animal Mycology (ISHAM) Zygomycosis Working Group is to improve the clinical and laboratory diagnosis of mucormycosis. The diagnostic tools generated from this study may help to significantly improve survival from mucormycosis worldwide. The study has three major objectives: to conduct a prospective international registration of patients with mucormycosis using a well-established global network of centres; to construct a predictive risk model for patients at risk for mucormycosis; and to establish an international archive of specimens of tissues, fluids, and organisms linked from the patients enrolled into the registry that will be used for development of leading edge molecular, proteomic, metabolic and antigenic systems for mucormycosis.",
keywords = "Diagnosis, Epidemiology, Mucormycosis, Network, Zygomycosis",
author = "Walsh, {Thomas J.} and Anna Skiada and Cornely, {Oliver A.} and Emmanuel Roilides and Ashraf Ibrahim and Theoklis Zaoutis and Andreas Groll and Olivier Lortholary and Kontoyiannis, {Dimitrios P.} and George Petrikkos",
year = "2014",
month = "12",
day = "1",
doi = "10.1111/myc.12249",
language = "English (US)",
volume = "57",
pages = "2--7",
journal = "Mycoses",
issn = "0933-7407",
publisher = "Wiley-Blackwell",
number = "s3",

}

TY - JOUR

T1 - Development of new strategies for early diagnosis of mucormycosis from bench to bedside

AU - Walsh, Thomas J.

AU - Skiada, Anna

AU - Cornely, Oliver A.

AU - Roilides, Emmanuel

AU - Ibrahim, Ashraf

AU - Zaoutis, Theoklis

AU - Groll, Andreas

AU - Lortholary, Olivier

AU - Kontoyiannis, Dimitrios P.

AU - Petrikkos, George

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Early diagnosis and initiation of amphotericin B (AmB) for treatment of mucormycosis increases survival from approximately 40% to 80%. The central objective of a new study of the European Confederation of Medical Mycology (ECMM) and the International Society for Human and Animal Mycology (ISHAM) Zygomycosis Working Group is to improve the clinical and laboratory diagnosis of mucormycosis. The diagnostic tools generated from this study may help to significantly improve survival from mucormycosis worldwide. The study has three major objectives: to conduct a prospective international registration of patients with mucormycosis using a well-established global network of centres; to construct a predictive risk model for patients at risk for mucormycosis; and to establish an international archive of specimens of tissues, fluids, and organisms linked from the patients enrolled into the registry that will be used for development of leading edge molecular, proteomic, metabolic and antigenic systems for mucormycosis.

AB - Early diagnosis and initiation of amphotericin B (AmB) for treatment of mucormycosis increases survival from approximately 40% to 80%. The central objective of a new study of the European Confederation of Medical Mycology (ECMM) and the International Society for Human and Animal Mycology (ISHAM) Zygomycosis Working Group is to improve the clinical and laboratory diagnosis of mucormycosis. The diagnostic tools generated from this study may help to significantly improve survival from mucormycosis worldwide. The study has three major objectives: to conduct a prospective international registration of patients with mucormycosis using a well-established global network of centres; to construct a predictive risk model for patients at risk for mucormycosis; and to establish an international archive of specimens of tissues, fluids, and organisms linked from the patients enrolled into the registry that will be used for development of leading edge molecular, proteomic, metabolic and antigenic systems for mucormycosis.

KW - Diagnosis

KW - Epidemiology

KW - Mucormycosis

KW - Network

KW - Zygomycosis

UR - http://www.scopus.com/inward/record.url?scp=84913616491&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84913616491&partnerID=8YFLogxK

U2 - 10.1111/myc.12249

DO - 10.1111/myc.12249

M3 - Article

VL - 57

SP - 2

EP - 7

JO - Mycoses

JF - Mycoses

SN - 0933-7407

IS - s3

ER -